Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

New deal builds on the success of a longstanding partnership in retinal health and the potential of CDR-Life's unique antibody fragment-based platform   Agreement provides potential for up to approx.

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

BostonGene, developer of the leading AI foundation model for cancer and the immune system, today announced that it will showcase its latest advances at the Association for Molecular Pathology (AMP) ...

A California woman on trial for taking four chickens from one of Perdue Farms' major poultry plants has put animal treatment ...

NOTE: Some of these events may have been canceled or postponed. Please check with the organizers. Call 843-873-9424 ext. 220 ...

This is just one of the grisly examples given in The Atlas Of Deadly Plants, a tome of toxic tales by expert gardener, ...

Advancements in research and ongoing clinical trials related to HDFN prevention and treatment can change HDFN care for the ...

There's no greater joy than the enjoyment of a garden filled with colourful and diverse vegetation, but not all plants and ...

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...

Optigo Biotherapeutics (“Optigo”), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr. Andreas Wallnöfer is joining its ...